Session Details

F085 Diversity, Equity, and Inclusion

Sun, Mar 10, 1:00 PM - 3:00 PM
Room 23C
2 CME Available Forum
View Map

DESCRIPTION

Open admission to eligible categories, no tuition or ticket

This symposium aims to highlight the importance of diversity, equity and inclusion in dermatology and research. It will also highlight considerations of the healthcare needs of diverse patient populations. This session is intended for a broad audience, where we hope to engage in valuable discussion and consider diversity of thought and experiences as they pertain to these topics. The session will feature current leaders in this work and will present opportunities for participants to learn more about and support this work as it relates to personal relationships, mentorship, sponsorship, research, education and advocacy.

LEARNING OBJECTIVES

1.

Discuss the importance of diversity, equity and inclusion (DEI) in dermatology and research.

2.

Discuss steps to improve inclusion, advocacy and care for religious minorities, sexual and gender diverse, and American Indian and Alaska Native populations.

SCHEDULE

8:00 PM

What the AAD is doing to promote DEI

Susan C. Taylor, MD, FAAD

8:15 PM

Pathway Programs

Henry W. Lim, MD, FAAD

8:30 PM

Impact of the SCOTUS decision on DEI initiatives

Arturo P Saavedra, MD, PhD, FAAD

8:45 PM

Considerations for inclusion, advocacy, and care for sexual and gender diverse populations in dermatology

Jon Klint Peebles, MD, FAAD

9:00 PM

Dermatologic care of American Indian and Alaska Native populations

Shannon Watson Zullo, MD

9:15 PM

Care of religious minorities in the US

Nour Kibbi, MD, FAAD

9:30 PM

The use of terminology for patients in research

Mya L. Roberson

9:45 PM

Diversity in clinical trials

Junko Takeshita, MD, PhD, FAAD

SPEAKERS

Nour Kibbi, MD, FAAD

Nour Kibbi, MD, FAAD

Henry W. Lim, MD, FAAD

Henry W. Lim, MD, FAAD

Janiene Luke, MD, FAAD

Janiene Luke, MD, FAAD

Jon Klint Peebles, MD, FAAD

Jon Klint Peebles, MD, FAAD

E. Nikki Pritchett, MPH, MD, FAAD

E. Nikki Pritchett, MPH, MD, FAAD

Mya L. Roberson

Mya L. Roberson

Arturo P Saavedra, MD, PhD, FAAD

Arturo P Saavedra, MD, PhD, FAAD

Junko Takeshita, MD, PhD, FAAD

Junko Takeshita, MD, PhD, FAAD

Susan C. Taylor, MD, FAAD

Susan C. Taylor, MD, FAAD

Shannon Watson Zullo, MD

Shannon Watson Zullo, MD

HANDOUTS

Login to view handouts

SPEAKER DISCLOSURES

Nour Kibbi, MD, FAAD

No financial relationships exist with ineligible companies.

Henry W. Lim, MD, FAAD

Beiersdorf, Inc. – Consultant(Fees); Cantabria Labs – Speaker(Fees); Eli Lilly – Consultant (1099 relationship)(Honoraria); Ferndale Laboratories, Inc. – Consultant(Fees); Incyte Corporation – Investigator(Grants/Research Funding); ISDIN – Consultant(Fees); L'Oreal USA Inc. – Consultant (1099 relationship)(Fees); La Roche-Posay – Investigator(Grants/Research Funding); La Roche-Posay Laboratoire Pharmaceutique – Speaker/Faculty Education(Fees); Laboratoire Dermatologiques d'Uriage – Speaker/Faculty Education(Honoraria); NAOS – Speaker(Fees); Patient-Centered Outcomes Research Institute – Investigator(Grants/Research Funding); PCORI – Investigator(Fees); Pfizer Inc. – Investigator(Grants/Research Funding), Speaker/Faculty Education(Honoraria); Pierre Fabre – Speaker(Fees); Primus Pharmaceuticals – Consultant (1099 relationship)(Honoraria); Skinosive – Consultant (1099 relationship)(Fees); Zerigo Health – Consultant (1099 relationship)(Honoraria);

Janiene Luke, MD, FAAD

Eli Lilly – Speaker(Honoraria); Sanofi/Regeneron – Speaker(Honoraria);

Jon Klint Peebles, MD, FAAD

Kaiser Permanente – Employee(Salary);

E. Nikki Pritchett, MPH, MD, FAAD

Kimberly Clark – Consultant (1099 relationship)(Fees);

Mya L. Roberson

No financial relationships exist with ineligible companies.

Arturo P Saavedra, MD, PhD, FAAD

No financial relationships exist with ineligible companies.

Junko Takeshita, MD, PhD, FAAD

Incyte – Consultant (1099 relationship)(Honoraria); Pfizer Inc. – Investigator(Grants/Research Funding);

Susan C. Taylor, MD, FAAD

AbbVie – Advisory Board(Honoraria); Allergan Aesthetics – Investigator(Grants/Research Funding); Arcutis, Inc. – Consultant(Honoraria); Armis Biopharma, Inc. – Advisory Board(No Compensation Received); Avita Medical – Advisory Board(Honoraria); Beiersdorf, Inc. – Advisory Board(No Compensation Received), Consultant(Honoraria), Speaker/Faculty Education(Honoraria); Biorez, Inc. – Advisory Board(Honoraria); Bristol-Myers Squibb – Consultant(Honoraria); Cara Therapeutics – Consultant(Honoraria); Catalyst Medical Education LLC – Speaker/Faculty Education(Honoraria); Concert Pharmaceuticals – Investigator(Grants/Research Funding); Croma-Pharma GmbH Austria – Investigator(Grants/Research Funding); Dermsquared – Speaker/Faculty Education(Honoraria); Dior – Consultant(Honoraria); Eli Lilly and Company – Advisory Board(No Compensation Received), Investigator(Grants/Research Funding); EPI Health – Advisory Board(Honoraria); Estee Lauder – Advisory Board(Honoraria); Evolus, Inc. – Advisory Board(Honoraria); Galderma Laboratories, L.P. – Advisory Board(Honoraria); GloGetter, Inc – Advisory Board(No Compensation Received); Hugel – Advisory Board(Honoraria); Incyte – Advisory Board(Honoraria); Johnson & Johnson Innovative Medicine – Advisory Board(No Compensation Received); L'Oreal – Advisory Board(No Compensation Received); L'Oreal USA Inc. – Advisory Board(Honoraria), Advisory Board(No Compensation Received); LearnSkin – Speaker/Faculty Education(Honoraria); Medscape – Advisory Board(Honoraria), Speaker/Faculty Education(Honoraria); Mercer Strategies, PA, LLC – Board of Directors(Honoraria), Employee(Fees); MJH Life Sciences – Speaker/Faculty Education(Honoraria); Pfizer Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Piction Health – Advisory Board(No Compensation Received); Sanofi – Consultant(Honoraria); Scientis – Advisory Board(Honoraria); Sun Pharmaceutical Industries Ltd. – Investigator(Grants/Research Funding); UCB – Advisory Board(Honoraria); Vichy Laboratoires – Advisory Board(Honoraria);

Shannon Watson Zullo, MD

No financial relationships exist with ineligible companies.